---
title: Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy
nct_id: NCT02086838
overall_status: COMPLETED
phase: PHASE4
sponsor: Ain Shams University
study_type: INTERVENTIONAL
primary_condition: Treatment of Iron Deficiency Anemia in Pregnancy
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02086838.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02086838"
ct_last_update_post_date: 2015-03-19
last_seen_at: "2026-05-12T06:43:42.784Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy

**Official Title:** Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy

**NCT ID:** [NCT02086838](https://clinicaltrials.gov/study/NCT02086838)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 212
- **Lead Sponsor:** Ain Shams University
- **Conditions:** Treatment of Iron Deficiency Anemia in Pregnancy
- **Start Date:** 2013-07
- **Completion Date:** 2014-12
- **CT.gov Last Update:** 2015-03-19

## Brief Summary

Evaluate the effect of iron supplementation using oral routes in comparison with total dose infusion of low molecular weight iron dextran in iron deficiency anemia during pregnancy.

## Detailed Description

Patients will be allocated to two groups of 106 each and to insure that everyone has the chance of participation, randomization will be guided by table of random numbers All women recruited in the study will be given 100 mg mebendazole tablets twice daily for 3 days for de-worming and 500 micro gram folic acid daily till the end of the study The required dose will be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status Total iron dose (mg) = weight (kg) X hemoglobin deficit {target hemoglobin (g/l)- Actual hemoglobin (g/l)} X 0.24 + 500 mg The total iron dose needed will be calculated by formula rounded to nearest multiple of 100 Group I includes pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® Smith-Kline Beecham, Egypt an affiliated co. to Glaxo Smith-Kline, according to the WHO guidelines for IDA control Group II includes pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R Pharmacosmos Denmark (Inspire Pharma Egypt) Inclusion criteria

* Maternal age 20-35 years old.
* Singleton pregnancy between 16 - 24 weeks
* Iron deficiency anemia with average hemoglobin ranging from 7-9 g/dL at the onset of the study

Exclusion criteris

* Extremes of reproductive age (less than 20 years old or more than 35 years old).
* Patients with multiple pregnancies.
* Anemia not linked to iron deficiency.
* Allergy to iron derivatives.
* Any medical disorder like diabetes or tuberculosis (TB), viral hepatitis cirrhosis, cardiovascular disease, renal disease, autoimmune disease, suspected acute infection, cancer.
* Those who had received parenteral iron treatment earlier within 3 months before the start of the study.
* Any obstetric complicating factors like pregnancy induced hypertension (PIH).
* Patients with history of chronic blood loss.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 35 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Maternal age 20-35 years old.
* Singleton pregnancy between 16 - 24 weeks.
* Iron deficiency anemia with average hemoglobin ranging from 7-9 g % at the onset of the study.

Exclusion Criteria:

* Extremes of reproductive age (less than 20 years old or more than 35 years old).
* Patients with multiple pregnancies.
* Anemia not linked to iron deficiency.
* Allergy to iron derivatives.
* Any medical disorder like diabetes or tuberculosis (TB), viral hepatitis cirrhosis, cardiovascular disease, renal disease, autoimmune disease, suspected acute infection, cancer.
* Those who had received parenteral iron treatment earlier within 3 months before the start of the study.
* Any obstetric complicating factors like pregnancy induced hypertension.
* Patients with history of chronic blood loss.
```

## Arms

- **Theragran Hematinic, oral iron, 120 mg elemental iron/** (ACTIVE_COMPARATOR) — pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
- **low molecular weight iron dextran, total dose infusion** (ACTIVE_COMPARATOR) — Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.

## Interventions

- **Theragran Hematinic** (DRUG)
- **low molecular weight iron dextran** (DRUG)

## Primary Outcomes

- **The proportion of patients who have been successfully treated** _(time frame: up to 8 weeks from comleting treatment)_ — The proportion of patients who have been successfully treated as evidenced by a hemoglobin concentration of \> 10.5 g% after 8 weeks from completing treatment (oral or total iron dose infusion therapy).

## Secondary Outcomes

- **Number of participants with adverse effects** _(time frame: up to 8 weeks after completing treatment)_

## Locations (1)

- Maternity Hospital, Faculty of Madicine, AinShams University, Cairo, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.maternity hospital, faculty of madicine, ainshams university|cairo||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02086838.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02086838*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*